The molecular basis for heterogeneity in the severity of cystic fibrosis;Les bases moleculaires de l'heterogeneite phenotypique dans la mucoviscidose

Annales de Biologie Clinique

Volumn 55, Issue 2, 1997, Pages 113-121

  Bienvenu, T ^a  

^a Lab de Biochim et de Genet Molec Hôpital Cochin ^*  (France)

Author keywords

congenital bilateral absence of the vas deferens; cystic fibrosis; DGGE; genotype; mutations; phenotype; transcript

Indexed keywords

CYSTIC FIBROSIS; DISEASE SEVERITY; GENE MUTATION; GENITAL MALFORMATION; GENOTYPE; HUMAN; MOLECULAR GENETICS; PHENOTYPE; REVIEW; VAS DEFERENS; GENETIC HETEROGENEITY; GENETICS; MUTATION;

CFTR PROTEIN, HUMAN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; MUTATION; PHENOTYPE;

EID: 0031088985     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Fiel SB. Clinical management of pulmonary disease in cystic fibrosis. Lancet 1993 ; 341 : 1070-4.
2. Highsmith WE, Lauranelli H, Burch MS, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994 ; 331 : 9754-980.
3. Rommens JM, Iannuzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989 ; 245 : 1059-65.
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene : cloning and characterization of complementary DNA. Science 1989 ; 245 : 1066-73.
5. Kerem B, Zielenski J, Buchanan JA, et al. Identification of the cystic fibrosis gene : genetic analysis. Science 1989 ; 245 : 1073-80.
6. Fanen P, Ghanem N, Vidaud M, et al. Molecular characterization of cystic fibrosis : 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions. Genomics 1992, 12 : 770-6.
7. Fernandez E, Bienvenu T, Desclaux Arramond F, Beldjord K, Kaplan JC, Beldjord C. Use of chemical clamps in denaturing gradient gel electrophoresis : application in the detection of the most frequent Mediterranean β thalassemic mutations. PCR Methods Appl 1993 ; 3 : 122-4.
8. Ferec C, Audrezet MP, Mercier B, Guillermit H, Moullier P, Quere L, Verlingue C. Detection of over 98 % cystic fibrosis mutations in a celtic population. Nature Genetique 1992, 1 : 88-191.
9. Bienvenu T, Cazeneuve C, Kaplan JC, Beldjord C. Mutation heterogeneity of cystic fibrosis in France : screening by denaturing gradient gel electrophoresis using psoralen-modified oligonucleotide. Hum Mutat 1995 ; 6 : 23-9.
10. Bienvenu T, Adjiman M, Thiounn N, et al. Molecular diagnosis of congenital absence of the vas deferens : analyses of the CFTR gene in 64 French patients. Ann Genet 1997, sous presse.
11. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis : analysis of the most common mutation (ΔF508). N Engl J Med 1990 ; 323 : 1517-22.
12. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutation. Lancet 1991 ; 337 : 631-4.
13. Borgo G, Mastella G, Gasparini P, Zorzanello A, Dora R, Pignatti PF. Pancreatic function and gene deletion F508 in cystic fibrosis. J Med Genet 1990 ; 27 : 665-9.
14. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992 ; 50 : 1178-84.
15. Santis G, Osborne L, Knight R, Hodson ME, Ramsay M. Genetic influences on pulmonary severity in cystic fibrosis. Lancet 1990 ; i : 294.
16. Passero MA, Passero M. Two fertile males with pulmonary disease and the 3849 + 10kbC → T/3659delC mutations. Pediatr Pulmonol 1994 ; 12 : 205.
17. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993 ; 73 : 1251-4.
18. Hubert D, Bienvenu T, Desmazes-Dufeu N, et al. Genotype-phenotype relationships in a cohort of cystic fibrosis adult patients. Eur Respir J 1996 ; 9 : 2207-14.
19. Kubesh P, Dork T, Wulbrand U, et al. Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet 1993 ; 341 : 189-93.
20. Gan KH, Heijerman HGM, Bakker W. Correlauon between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1994 ; 330 : 865-6.
21. Rave-Harel N, Chiba-Falek O, Kerem E, et al. The level of normal CFTR transcripts required for normal pulmonary function. Pediatr Pulmonol 1996 ; 13 : 246.
22. Macek Jr M, Mickle J, Vavrova V, et al. The identification of a possible revenant mutation (V12121) in two czech ΔF508 homozygous siblings with cystic fibrosis and delayed onset of pancreatic insufficiency. Israel J Med Sci 1996 ; 32 : S11-2.
23. Kiesewetter S, Macek Mjr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nature Genetique 1993 ; 5 : 274-8.
24. Dean M, Osborne L, Santis G, Knight R. Association of HLA and ILRA alleles with pulmonary disease severity. Pediatr Pulmonol 1994 ; 10 : 121.
25. Radzioch D, Gosselin D, Boule M, Skamene E, DeSanctis J. Genetically controlled resistance to infection with Pseudomonas aeruginosa correlates with rapid transient augmentation of TNFα production in mice. Pediatr Pulmonol 1994 ; 10 : 278.
26. Kerem E, Nissim M, Zvi A, Yahav Y, Augarten A, Chiba O, Moran I, Kerem B. Extremely high variability of clinical presentation among patients carrying the missense mutation G85E. Pediatr Pulmonol 1994 ; S10 : 120.
27. Estivill X, Ortigosa L, Perez-Frias J, et al. Clinical characteristics of 16 cystic fibrosis patients with the missense mutation R334W, pancreatic insufficiency mutation with variable age of onset and interfamilial clinical differences. Hum Genet 1995 ; 95 : 331-6.
28. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nature Genetique 1996 ; 12 : 280-7.
29. Howard M, Frizell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 1996 ; 2 : 467-9.
30. Bedwell D, Kaenjak A, Benos D, et al. Aminoglycosides restore CPTR function in the IB3-1 CF cell line by suppressing premature stop mutations. Pediatr Pulmonol 1996 ; 13 : 258.
31. Bienvenu T, Claustres M. Les bases moléculaires de la mucoviscidose et de l'agénésie bilatéraie des canaux déférents. Contracept Fertil Sex 1996 ; 24 : 495-500.
32. Dumur V, Gervais R, Rigot JM, et al. Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane conductance regulator (CFTR) : correlation between genotype and phenotype. Hum Genet 1996 ; 97 : 7-10.
33. Mickle J, Milunsky A, Amos JA, Oates RD. Congenital unilateral absence of the vas deferens : a heterogeneous disorder with two distinct subpopulations based upon aetiology and mutational status of the cystic fibrosis gene. Hum Reprod 1995 ; 10 : 1728-35.
34. Jarvi K, Zielenski J, Wilschanski M, et al. High frequency of CFTR mutations or variants in men with oligospermic infertility. Pediatr Pulmonol 1996 ; 13 : 247.
35. Sharer NM, Malone G, Haworth A, Scharz MJ, Braganza JM. Super M. Increased CFTR mutations in chronic pancreatitis. Israel J Med Sciences 1996 ; 32 : S175.
36. Pignatti PF, Bombieri C, Mango C, Benetazzo M, Luisetti M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 1995 ; 4 : 635-9.
37. Girodon E, Cazeneuve C, Costes B, et al. Involvement of the cystic fibrosis gene in adults having disseminated bronchiectasis. Eur J Hum Genet 1996 ; 4S1 : 91.
38. Clark R, Mac Mahon R, Bilton D, et al. Cystic fibrosis mutations in bronchiectasis patients. Eur J Hum Genet 1996, 4S1 : 104.
39. Weiner Miller P, Hamosh A, Macek M Jr, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996, 59 : 45-51.